Cimeio is the leader of the field of epitope editing and is developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ (SCIP), novel immunotherapies which have the potential to transform treatment of hematologic diseases. Cimeio develops state-of-the-art immunotherapies, along with paired, modified variants of naturally occurring cell surface proteins in HSCs. These novel epitope edited variants maintain their function but are resistant to depletion when targeted by the paired immunotherapy which has high affinity for the wild-type version of these proteins. These immunotherapies have significant therapeutic potential, which Cimeio is using to develop curative treatments for patients with hematologic malignancies, autoimmune disorders, and genetic diseases. Shielded Cell and Immunotherapy Pairs and SCIP are trademarks of Cimeio Therapeutics, Inc.